Welcome to our dedicated page for Pds Biotechnology Corporation SEC filings (Ticker: PDSB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PDS Biotechnology Corporation filings document the formal disclosures of a late-stage biotechnology company developing targeted immunotherapies for cancer. Recent 8-K reports furnish operating and financial results, business updates, corporate presentations, and press-release exhibits covering PDS0101, VERSATILE-003, PDS01ADC, and related clinical and biomarker data.
The filing record also includes material-event disclosures on FDA and IND protocol matters, Nasdaq listing-compliance correspondence, exhibit filings, capital-structure topics, shareholder voting matters, and the risk and forward-looking-statement language attached to the company’s clinical-development and financing activities.
PDS Biotechnology reported full-year 2025 results and detailed progress in its cancer immunotherapy pipeline. Net loss narrowed to $34.5 million, or $0.74 per share, from $37.6 million, or $1.03, in 2024 as operating expenses declined.
Research and development spending fell to $19.0 million and general and administrative expenses to $12.5 million, bringing total operating expenses down to $31.5 million. Cash and cash equivalents were $26.7 million at year-end, with total stockholders’ equity of $9.3 million and long-term debt of $11.7 million.
The company updated its PDS0101 Phase 3 VERSATILE-003 trial, incorporating progression-free survival as an interim primary endpoint, which it expects will shorten trial duration and reduce costs while keeping overall survival for full approval. PDS Biotech also highlighted new U.S. and Japanese patents that extend Versamune® platform protection into the 2040s.
PDS Biotechnology Corp reported that President and CEO Frank Bedu-Addo received a grant of stock options covering 548,782 shares of the company’s stock. The options were granted at an exercise price of $0.00 per share as an employee stock option award.
According to the terms, 25% of the underlying shares will vest and become exercisable on January 12, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on his continued service with the company through each vesting date.
PDS Biotechnology Corp reported that Chief Scientific Officer Gregory Conn received an employee stock option grant covering 150,000 shares on January 12, 2026. The option was awarded at an exercise price of $0.00 per share.
According to the vesting terms, 25% of the underlying shares will vest and become exercisable on January 12, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on Conn’s continued service with the company through each vesting date.
PDS Biotechnology Corp reported that Chief Medical Officer Kirk V. Shepard acquired an employee stock option covering 300,000 shares of common stock. The option was granted as a derivative security and is held directly after the transaction.
According to the vesting terms, 25% of the underlying shares will vest and become exercisable on January 12, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on Dr. Shepard’s continued service with the company through each vesting date.
Boesgaard Lars reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp reported that Chief Financial Officer Lars Boesgaard received a grant of employee stock options covering 300,000 shares on January 12, 2026. These options give him the right to buy company stock in the future.
The options vest over four years. Twenty‑five percent of the underlying shares will vest and become exercisable on January 12, 2027, and the remaining 75% will vest in 36 equal monthly installments after that date, as long as he continues to serve the company through each vesting date.
Brown Spencer D. reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp reported that Senior VP and General Counsel Spencer D. Brown received a grant of 300,000 employee stock options on January 12, 2026. According to the terms, 25% of the options vest on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on his continued service.
Toutain Stephan reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp reported that its Chief Operating Officer, Stephan Toutain, received a grant of employee stock options on January 12, 2026. The award covers 300,000 options with a right to buy company shares, recorded as a direct ownership position.
The options vest over four years: 25% of the underlying shares vest and become exercisable on January 12, 2027, and the remaining 75% vest in 36 equal monthly installments thereafter, as long as Toutain continues serving the company through each vesting date.
PDS Biotechnology Corp director receives stock option grant
PDS Biotechnology Corp director Gregory Gene Freitag was granted an employee stock option for 54,876 shares of common stock on the reported date. The option has an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
The stock option will vest in full and become fully exercisable on the first anniversary of the grant date, provided Freitag continues to serve as a director through that date. After this award, he holds 54,876 derivative securities directly in the form of this option grant.
Iliev Ilian reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp director Ilian Iliev received a grant of 54,876 employee stock options on January 12, 2026. These options were awarded at no cost as an equity incentive and will vest in full on the first anniversary of the grant date, provided he continues serving as a director.
Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp director Ali-Jackson Kamil received a grant of 54,876 employee stock options on January 12, 2026. These options are held as direct ownership and were awarded at a reported price of $0.00 per option. The entire grant will vest and become fully exercisable on the first anniversary of the grant date, provided Kamil continues to serve as a director through that date.